Drugs for Adult Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 164)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Temozolomide |
Approved, Investigational |
Phase 3,Phase 2,Phase 1 |
|
85622-93-1 |
5394
|
|
Synonyms:
3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
85622-93-1
8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
AC1L1K9B
AC-758
BIDD:GT0204
Bio-0147
BRN 5547136
C047246
C6H6N6O2
CCRG 81045
CCRG-81045
CCRIS 8996
CHEBI:153686
CHEMBL810
CID5394
CPD000466338
D06067
DB00853
Essex brand of temozolomide
HMS2051O12
HMS2090B08
I06-0149
I14-1943
LS-80558
M B 39831
m & b 39831
M & B 39831
m And b 39831
m And b-39831
|
M&B 39831
M&B-39831
M-39831
MB 39831
Methazolastone
MLS000759447
MLS001424028
MLS002701861
NCGC00167429-01
NCGC00167429-02
NCI60_003316
NSC 362856
NSC362856
NSC-362856
SAM001246636
Sch 52365
SCH 52365
Sch-52365
Schering brand of temozolomide
Schering-Plough brand of temozolomide
SMR000466338
STK623541
Temodal
Temodal (TN)
Temodar
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
temozolomide
Temozolomide
Témozolomide
Temozolomide (JAN/USAN/INN)
Temozolomide [INN:BAN]
Temozolomidum
Temozolomidum [Latin]
TL8005593
TMZ
TMZ-Bioshuttle
UNII-YF1K15M17Y
ZINC01482184
|
|
| 2 |
|
Lomustine |
Approved, Investigational |
Phase 2, Phase 3 |
|
13010-47-4 |
3950
|
|
Synonyms:
(Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian]
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]
1-(2-chloroethyl)-3-cyclohexylnitrosourea
1-(2-Chloroethyl)-3-cyclohexylnitrosourea
13010-47-4
AC-10564
AC1L1H2T
AI3-52779
Belustine
Bristol myers squibb brand OF lomustine
Bristol Myers Squibb Brand of Lomustine
Bristol-myers squibb brand OF lomustine
Bristol-Myers Squibb Brand of Lomustine
BRN 2125058
C9H16ClN3O2
CCNU
CCNU [Chloroethyl nitrosoureas]
CCRIS 860
Cecenu
CeeNU
CeeNU (TN)
CeeNU, CCNU, Lomustine
CHEMBL514
Chloroethylcyclohexylnitrosourea
CID3950
CINU
Cyclohexyl chloroethyl nitrosourea
D00363
D008130
DB01206
EINECS 235-859-2
FT-0083566
HMS2090A17
HSDB 6519
I06-0087
|
ICIG 1109
Lomustina
Lomustina [INN-Spanish]
lomustine
Lomustine
Lomustine (USAN/INN)
Lomustine [USAN:BAN:INN]
Lomustine medac brand
Lomustine medac Brand
Lomustinum
Lomustinum [INN-Latin]
LS-728
medac Brand of Lomustine
Medac brand OF lomustine
MolPort-001-768-818
N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea
N-(2-Chloroethyl)-n'-cyclohexyl-N-nitrosourea
N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea
NCGC00167466-01
NCI60_041743
NCI-C04740
NCIMech_000220
NPFAPI-06
NSC 79037
NSC79037
NSC-79037
OR5087
RB 1509
Rhone Poulenc Rorer Brand of Lomustine
Rhône poulenc rorer brand OF lomustine
Rhone-Poulenc Rorer Brand of Lomustine
Rhône-poulenc rorer brand OF lomustine
S1840_Selleck
SRI 2200
UNII-7BRF0Z81KG
WLN: L6TJ AMVNNO&2G
ZINC03831006
|
|
| 3 |
|
Procarbazine |
Approved, Investigational |
Phase 2, Phase 3 |
|
671-16-9 |
4915
|
|
Synonyms:
1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine
1-Methyl-2-(P-(isopropylcarbamoyl)benzyl)hydrazine
2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine
2-(P-Isopropylcarbamoylbenzyl)-1-methylhydrazine
366-70-1 (mono-hydrochloride)
4-((2-methylhydrazino)Methyl)-N-isopropylbenzamide
4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide
4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide
671-16-9
AC1L1J8E
AC-4547
Ambap671-16-9
Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)- (9CI)
BIDD:GT0183
BPBio1_001369
BRN 0958270
BSPBio_001244
C07402
C12H19N3O
Cambridge laboratories brand OF procarbazine hydrochloride
CAS-366-70-1
CB 400-497
CCRIS 2389
CHEMBL1321
CID4915
D08423
DB01168
EINECS 211-582-2
HMS2090J09
HSDB 3250
Hydrochloride, procarbazine
I01-8931
Ibenzmethyzin
Ibenzmethyzine
IBZ
LS-7671
Matulane
MBH
MIH
MolPort-005-940-370
Monohydrobromide, procarbazine
Monohydrochloride, procarbazine
N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide
N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide
N-4-Isopropylcarbamoylbenzyl-n'-methylhydrazine
N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine
Natulan
|
Natulanar
NCGC00016438-01
NCGC00016438-02
NCI60_041703
NCIOpen2_004074
N-isopropyl-4-[(2-methylhydrazino)methyl]benzamide
N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide
N-Isopropyl-a-(2-methylhydrazino)-P-toluamide
N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide
N-Isopropyl-alpha-(2-methylhydrazino)-P-toluamide
N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide
N-Isopropyl-P-(2-methylhydrazinomethyl)-benzamide
N-Isopropyl-α-(2-methylhydrazino)-p-toluamide
N-Isopropyl-α-(2-methylhydrazino)-P-toluamide
NSC-77213
p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
P-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
p-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide
PCX
Prestwick0_001112
Prestwick1_001112
Prestwick2_001112
Prestwick3_001112
Procarbazin
Procarbazin [German]
Procarbazina
Procarbazina [INN-Spanish]
procarbazine
Procarbazine
Procarbazine (INN)
Procarbazine [INN:BAN]
Procarbazine hydrochloride
Procarbazine monohydrobromide
Procarbazine monohydrochloride
Procarbazine Monohydrochloride
Procarbazinum
Procarbazinum [INN-Latin]
Ro 4-6467
Ro 4-6467/1
Roche brand OF procarbazine hydrochloride
Sigma tau brand OF procarbazine hydrochloride
Sigma-tau brand OF procarbazine
Sigma-tau brand OF procarbazine hydrochloride
SPBio_003112
SRI-10847
UNII-35S93Y190K
|
|
| 4 |
|
Vincristine |
Approved, Investigational |
Phase 2, Phase 3 |
|
2068-78-2, 57-22-7 |
5978
|
|
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
Cellcristin
CHEBI:28445
CID5978
Citomid
D08679
DB00541
EINECS 200-318-1
Farmistin
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
LS-228
Marqibo
NCGC00163700-01
NCI60_026703
NCI-C04864
NSC-67574
Onco TCS
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Onkocristin
|
PFS, Vincasar
Sulfate, vincristine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristin bristol
Vincristin medac
Vincristina
Vincristina [DCIT]
vincristine
Vincristine
Vincristine (INN)
Vincristine [INN:BAN]
Vincristine sulfate
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristinum
Vincristinum [INN-Latin]
Vincrisul
Vincrstine
Vincrystine
Vinkristin
Vintec
Z-D-Val-lys(Z)-OH
Z-D-Val-Lys(Z)-OH
|
|
| 5 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 3 |
|
437-38-7 |
3345
|
|
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
Cephalon brand OF fentanyl buccal oravescent
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
fentanyl
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl CII
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
Fentanyl-50
|
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
Fentora
HSDB 3329
IONSYS
Janssen pharmaceutica brand OF fentanyl
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
Nasalfent
NCGC00168252-01
N-phenethyl-4-(N-propionylanilino)piperidine
N-Phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Transmucosal oral fentanyl citrate
UNII-UF599785JZ
|
|
| 6 |
|
Donepezil |
Approved |
Phase 3,Phase 2 |
|
120014-06-4 |
3152
|
|
Synonyms:
( inverted exclamation markA)-E 2020
120014-06-4
1-Benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine hydrochloride
1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one
AB1004836
AC1L1FAE
AC-6969
AKOS000277311
Aricept
Aricept odt
Aricept ODT
C24H29NO3
CHEBI:53289
CHEMBL502
CID3152
D07869
DB00843
Domepezil
Donaz
Donaz (TN)
|
Donepezil
Donepezil (INN)
Donepezil [INN:BAN]
Donepezil hydrochloride
Donepezilium oxalate trihydrate
Donepezilo
Donepezilum
Eranz
I06-0343
KBio2_002144
KBio2_004712
KBio2_007280
KBioSS_002144
LS-81819
MolPort-000-881-588
MolPort-003-847-014
NCGC00167537-01
Oprea1_188452
Spectrum_001664
Spectrum5_001662
TL8000531
UNII-8SSC91326P
|
|
| 7 |
|
Pancreatic Polypeptide |
Investigational |
Phase 3 |
|
59763-91-6 |
|
| 8 |
|
Alkylating Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 9 |
|
Antineoplastic Agents, Alkylating |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 10 |
|
Antimitotic Agents |
|
Phase 2, Phase 3,Phase 1 |
|
|
|
| 11 |
|
Antineoplastic Agents, Phytogenic |
|
Phase 2, Phase 3,Phase 1 |
|
|
|
| 12 |
|
Narcotics |
|
Phase 3 |
|
|
|
| 13 |
|
Adjuvants, Anesthesia |
|
Phase 3 |
|
|
|
| 14 |
|
Analgesics |
|
Phase 3,Phase 2 |
|
|
|
| 15 |
|
Anesthetics, Intravenous |
|
Phase 3 |
|
|
|
| 16 |
|
Liver Extracts |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
| 17 |
|
Anesthetics, General |
|
Phase 3 |
|
|
|
| 18 |
|
Anesthetics |
|
Phase 3 |
|
|
|
| 19 |
|
Analgesics, Opioid |
|
Phase 3 |
|
|
|
| 20 |
|
Central Nervous System Depressants |
|
Phase 3,Phase 2 |
|
|
|
| 21 |
|
Peripheral Nervous System Agents |
|
Phase 3,Phase 2 |
|
|
|
| 22 |
|
Cola |
|
Phase 3,Phase 1 |
|
|
|
| 23 |
|
Cholinesterase Inhibitors |
|
Phase 3,Phase 2 |
|
|
|
| 24 |
|
Neurotransmitter Agents |
|
Phase 3,Phase 2,Early Phase 1,Not Applicable |
|
|
|
| 25 |
|
Nootropic Agents |
|
Phase 3,Phase 2 |
|
|
|
| 26 |
|
Cholinergic Agents |
|
Phase 3,Phase 2 |
|
|
|
| 27 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
|
|
Synonyms:
216974-75-3
antiVEGF
Anti-VEGF Humanized Monoclonal Antibody
anti-VEGF monoclonal antibody
Anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
rhuMAb-VEGF
|
|
| 28 |
|
Dasatinib |
Approved, Investigational |
Phase 2 |
|
302962-49-8 |
3062316
|
|
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
(18F)-N-(2-chloro-6-Methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
anh. dasatinib
Anh. dasatinib
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS Dasatinib
BMS354825
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
dasatinib
Dasatinib
Dasatinib (anh.)
dasatinib (anhydrous)
Dasatinib (USAN)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
|
dasatinibum
Dasatinibum
DB01254
EC-000.2122
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-METHYLPHENYL)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-Methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
NSC732517
NSC-732517
S1021_Selleck
Sprycel
SPRYCEL (TN)
Spyrcel
UNII-X78UG0A0RN
|
|
| 29 |
|
Lenograstim |
Approved, Investigational |
Phase 2,Phase 1 |
|
135968-09-1 |
|
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
|
|
| 30 |
|
Busulfan |
Approved, Investigational |
Phase 2 |
|
55-98-1 |
2478
|
|
Synonyms:
1, {4-Bis[methanesulfonoxy]butane}
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis(methanesulphonoxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Butanediol dimethanesulfonic acid
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethanesulphonic acid
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonoxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
acid, tetramethylene ester
AI3-25012
AKOS003614975
alkylating agent: crosslinks guanine residues
Ambap55-98-1
AN 33501
B1022
B2635_FLUKA
B2635_SIGMA
Bisulfex
Bisulphex
BRN 1791786
BSPBio_001920
Busilvex
busulfan
Busulfan
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Busulfan (JP15/USP/INN)
Busulfan [INN:JAN]
Busulfan glaxosmithkline brand
Busulfan GlaxoSmithKline Brand
Busulfan orphan brand
Busulfan Orphan Brand
Busulfan wellcome
Busulfan Wellcome
Busulfan wellcome brand
Busulfan Wellcome Brand
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Busulphano
Busulphanum
butane-1,4-diyl dimethanesulfonate
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
Citosulfan
CPD000058613
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
glaxo Wellcome brand OF busulfan
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline brand OF busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
|
GT 2041
GT 41
HMS1920I07
HMS2091O09
HMS502K09
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
Leucosulfan
Leucosulphan
LS-1358
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MLS001076666
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myléran
MYLERAN (TN)
Myleran tablets
Myleran Tablets
Myleran, Busulfex, Busulfan
Mylerlan
n-Butane-1,3-di(methylsulfonate)
N-Butane-1,3-di(methylsulfonate)
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI60_041640
NCI-C01592
NCIMech_000192
NINDS_000847
NSC 750
NSC750
NSC-750
NSC-750sulphabutin
Orphan brand OF busulfan
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
Spectrum_000092
SPECTRUM1500152
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
ST50825921
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene {bis[methanesulfonate]}
Tetramethylene bis(methanesulfonate)
Tetramethylene bis(methanesulfonic acid)
Tetramethylene bis(methanesulphonate)
Tetramethylene bis(methanesulphonic acid)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene Dimethane Sulfonate
Tetramethylenester kyseliny methansulfonove
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
Wellcome brand OF busulfan
Wellcome Brand of Busulfan
Wellcome, busulfan
Wellcome, Busulfan
WLN: WS1&O4OSW1
X 149
|
|
| 31 |
|
Thiotepa |
Approved, Investigational |
Phase 2 |
|
52-24-4 |
5453
|
|
Synonyms:
Girostan
Tepadina
Tespa
Tespamin
thio Tepa
Thiophosphamide
|
Thioplex
thio-Tepa
Thiotepa
Triethylenethiophosphoramide
Tris(1-aziridinyl)phosphine sulfide
|
|
| 32 |
|
Sirolimus |
Approved, Investigational |
Phase 2,Phase 1 |
|
53123-88-9 |
46835353
5284616
6436030
|
|
Synonyms:
(-)-rapamycin
(-)-Rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AC-722
Ambotz53123-88-9
Antibiotic AY 22989
AY 22989
AY22989
AY-22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
FT-0082351
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
|
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MolMap_000043
MolPort-003-959-433
MS-R001
NCGC00021305-05
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
Rapammune
Rapamune
Rapamune (TN)
rapamycin
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin from Streptomyces hygroscopicus
Rapamycin Immunosuppressant Drug
RPM
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
sirolimus
Sirolimus
Sirolimús
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
Sirolimusum
SMP1_000255
SMR000058564
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
Wy 090217
WY-090217
|
|
| 33 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2,Phase 1 |
|
22916-47-8 |
4189
|
|
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
Aflorix(nitrate)
AKOS001574474
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
Brentan
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
Conofite(nitrate)
CPD-4501
D00416
Dactarin
Daktarin IV
DB01110
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Esteve brand OF miconazole
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
Lotrimin AF(nitrate)
LS-78378
MCZ
Micantin (nitrate)
Miconasil nitrate
Miconasil Nitrate
Miconazol
|
Miconazol [INN-Spanish]
miconazole
Miconazole
Miconazole (JP15/USP/INN)
Miconazole [USAN:BAN:INN:JAN]
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MJR 1762
MLS002222203
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
Nitrate, miconasil
Nitrate, miconazole
Novo-Miconazole Vaginal Ovules
NSC 170986
NSC169434
NSC170986
Oprea1_091955
Prestwick_335
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
Spectrum_000965
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
STK834405
STOCK1S-93556
UNII-7NNO0D7S5M
Vusion
Zimycan
|
|
| 34 |
|
Everolimus |
Approved |
Phase 2,Phase 1 |
|
159351-69-6 |
70789204
6442177
|
|
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
001, RAD
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Certican
CERTICAN(R)
CHEMBL1201755
D02714
DB01590
everolimus
Everolimus
|
évérolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD, SDZ
RAD001
RAD-001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
RAD-001C
S1120_Selleck
SDZ RAD
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
|
|
| 35 |
|
Irinotecan |
Approved, Investigational |
Phase 2,Phase 1 |
|
100286-90-6, 97682-44-5 |
60838
|
|
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
7-Ethyl-10-hydroxycamptothecin
97682-44-5
AC1L1U0Z
AC1Q6PGI
AC-7469
Bio-0054
Biotecan
Biotecan (TN)
BRD-K08547377-003-02-4
BSPBio_002346
C16641
C33H38N4O6
Campothecin-11
Campto
Camptosar
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
CHEBI:105985
CHEMBL481
CID60838
CP0
CPT 11
CPT-11
D08086
DB00762
|
FT-0083650
HSDB 7607
Irinophore C
irinotecan
Irinotecan
Irinotecan (INN)
Irinotecan [INN:BAN]
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan Hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan Hydrochloride Trihydrate
IRINOTECAN HYDROCHLORIDE Trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
LS-44589
NCI60_005051
NK012 Compound
NSC728073
S1198_Selleck
sn 38
sn-38
sn38 CPD
TL8006026
UNII-7673326042
|
|
| 36 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4, 341031-54-7 |
5329102
|
|
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
5-(5-fluoro-2-oxo-1,2-Dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
|
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU010398
SU-010398
Su-011248
SU011248
SU011248 L-malate salt
SU-011248 L-malate salt
SU11248
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
Sunitanib
sunitinib
Sunitinib
Sunitinib (free base)
Sunitinib (INN)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
sunitinibum
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
|
|
| 37 |
|
Carmustine |
Approved, Investigational |
Phase 2,Phase 1 |
|
154-93-8 |
2578
|
|
Synonyms:
1,3-Bis(.beta.-chloroethyl)-1-nitrosourea
1,3-Bis(2-chloroethyl)-1-nitrosourea
1,3-Bis(2-chloroethyl)nitrosourea
1,3-Bis(beta-chloroethyl)-1-nitrosourea
1,3-BIS(CHLOROETHYL)-1-NITROSOUREA
154-93-8
AC-10563
AC1L1DZQ
AI3-52216
BCNU
BCNU [Chloroethyl nitrosoureas]
Becenum
Becenun
Bi CNU
Bicnu
BiCNU
BiCNU (TN)
Bio-0118
Bis(2-chloroethyl)1-nitrosourea
Bis(2-chloroethyl)nitrosourea
Bis(chloroethyl)nitrosourea
Bischlorethylnitrosourea
Bischlorethylnitrosurea
Bischloroethyl nitrosourea
Bischloroethyl nitrosourea [Chloroethyl nitrosoureas]
bis-chloroethylnitrosourea
Bischloroethylnitrosourea
Bis-N,N'-(chloroethyl)nitrosourea
BRN 2049744
C 0400
C0400_SIGMA
C5H11Cl2N3O2
Carmubris
Carmustin
Carmustina
Carmustina [INN-Spanish]
carmustine
Carmustine
Carmustine (USAN/INN)
Carmustine [USAN:INN:BAN]
carmustine in ethanol
Carmustinum
Carmustinum [INN-Latin]
CCRIS 810
CHEBI:3423
CHEMBL513
CID2578
D002330
D00254
DB00262
DivK1c_000835
DTI 015
|
EINECS 205-838-2
EU-0100188
FDA 0345
FIVB
FT-0083563
Gliadel
Gliadel Wafer
Gliadel, BCNU, NSC-409962, Becenun, Carmustine
HMS2092J22
HMS502J17
I14-11976
IDI1_000835
KBio1_000835
KBio2_000745
KBio2_003313
KBio2_005881
KBioGR_001296
KBioSS_000745
Lopac0_000188
Lopac-C-0400
LS-890
MLS001333962
MolPort-003-665-505
N,N'-bis(2-chloroethyl)-N-nitrosourea
N,N'-Bis(2-chloroethyl)-N-nitrosourea
N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA
NCGC00015204-01
NCGC00015204-02
NCGC00015204-06
NCGC00093665-01
NCGC00093665-02
NCGC00093665-03
NCGC00093665-04
NCI60_003931
NCI-C04773
NINDS_000835
Nitrumon
NSC 409962
NSC409962
NSC-409962
Prestwick_997
S1521_Selleck
SK 27702
SMR000058426
Spectrum_000265
Spectrum4_000888
Spectrum5_000920
SRI 1720
STK624770
UNII-U68WG3173Y
WLN: ONN2GVM2G
ZINC03830387
|
|
| 38 |
|
Etoposide |
Approved |
Phase 2,Phase 1 |
|
33419-42-0 |
36462
|
|
Synonyms:
(−)-etoposide
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4-demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
alpha-D-Glucopyranosyl isomer etoposide
Ambap33419-42-0
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bio1_000489
Bio1_000978
Bio1_001467
BPBio1_000673
BRD-K37798499-001-02-5
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
BSPBio_000611
C01576
CCRIS 2392
Celltop
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl epipodophyllotoxin ethylidine glucoside
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
eto GRY
eto-GRY
Etomedac
ETOP
Etopol
Etopophos
Etopophos (phosphate salt)
Etopos
|
etoposide
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido [INN-Spanish]
etoposido Ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Etosid
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
Lastet
Lemery brand OF etoposide
LS-1214
Medac brand OF etoposide
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
nchembio.573-comp8
nchembio873-comp2
NK 171
Novartis brand OF etoposide
NSC 141540
NSC141540
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Prestwick_211
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Riboposid
Ribosepharm brand OF etoposide
S1225_Selleck
SAM001246880
Sanfer brand OF etoposide
SMR000112002
SPBio_002532
ST056353
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Toposar
trans-Etoposide
UNII-6PLQ3CP4P3
Vepesid
VePesid
VePESID (TN)
Vepesid J
Vepeside
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16 (pharmaceutical)
VP 16213
VP 16-213
VP-16
VP-16-213
ZINC03830818
ZINC03938684
Zuyeyidal
|
|
| 39 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907
|
|
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
|
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
| 40 |
|
Cisplatin |
Approved |
Phase 2,Phase 1 |
|
15663-27-1 |
2767
441203
84093
|
|
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatin
Cisplatine
cisplatino
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
|
CPDC
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
| 41 |
|
Modafinil |
Approved, Investigational |
Phase 2 |
|
68693-11-8 |
4236
|
|
Synonyms:
2-((diphenylmethyl)sulfinyl)acetamide
2-((Diphenylmethyl)sulfinyl)acetamide
Alertec
Benzhydrylsulfinylacetamide
CEPA brand OF modafinil
Cephalon brand OF modafinil
Cephalon brand OF modafinil, reformulated
Dea No. 1680
Draxis brand OF modafinil
Lafon brand OF modafinil
Merckle brand OF modafinil
modafinil
|
Modafinil
Modafinil [Usan:Inn]
Modafinilo
Modafinilo [Spanish]
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Nourypharma brand OF modafinil
Provigil
Sparlon
Vigil
|
|
| 42 |
|
Pregabalin |
Approved, Illicit, Investigational |
Phase 2 |
|
148553-50-8 |
5486971
|
|
Synonyms:
(3S)-3-(aminomethyl)-5-methylhexanoic acid
(R-)-3-isobutyl GABA
(R-)-3-Isobutyl gaba
(S)-3-(Aminomethyl)-5-methylhexanoic acid
(S)-3-Isobutyl gaba
(S)-3-Isobutyl GABA
(S+)-3-isobutyl gaba
(S+)-3-isobutyl GABA
121GE001
148553-50-8
3 Isobutyl gaba
3-(Aminomethyl)-5-methylhexanoic acid
3-isobutyl GABA
3-Isobutyl gaba
3-Isobutyl GABA
AC-1158
AC1NUP03
AKOS005145504
C080245
C8H17NO2
CHEBI:236161
CHEMBL1059
CI 1008
|
CI-1008
CID5486971
D02716
DB00230
FT-0080911
GABA, 3-isobutyl
HSDB 7530
LS-75191
Lyrica
Lyrica (TN)
MolPort-000-861-733
PD 144723
PD-144723
Pregabalin
Pregabalin (JAN/USAN/INN)
Pregabalin [USAN]
Pregabalina
Pregablin
S1731_Selleck
SBB062901
TL8001062
TOS-BB-0910
UNII-55JG375S6M
|
|
| 43 |
|
Levetiracetam |
Approved, Investigational |
Phase 2 |
|
102767-28-2 |
441341
|
|
Synonyms:
(-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
(2S)-2-(2-oxopyrrolidin-1-yl)butanamide
(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
102767-28-2
AC-1479
AC1NR4PY
alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
BIDD:GT0242
C8H14N2O2
CHEMBL1286
CID5284583
CPD000466303
e Keppra
Etiracetam
Etiracetam levo-isomer
Etiracetam, R-isomer
etiracetam, S-isomer
Etiracetam, S-isomer
FT-0082600
HMS2051D07
HMS2089L20
Keppra
Keppra XR
Keppra, Keppra XR),Levetiracetam
L-059
levetiracetam
Levetiracetam
Levetiracetam [INN]
|
Levetiracetame
Levetiracetamum
Levetiracetamum [INN-Latin]
Levetiractam
Leviteracetam
Levitiracetam
LS-137054
MLS000759403
MLS001424069
MolPort-003-848-377
NCGC00186028-01
S1356_Selleck
SAM001246539
SBB070161
SIB-S1
SMR000466303
TL8000131
Torleva
UCB brand OF levetiracetam
Ucb L059
ucb L060
Ucb L060
UCB-22059
UCB-L 059
Ucb-L059
UCB-L059
Ucb-L060
ZINC01547851
|
|
| 44 |
|
Sodium Citrate |
Approved, Investigational |
Phase 2 |
|
68-04-2 |
|
|
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
|
Sodium citrate, anhydrous
Sodium citrate,anhydrous
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
| 45 |
|
Carboplatin |
Approved |
Phase 2,Phase 1 |
|
41575-94-4 |
10339178
38904
498142
|
|
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
Blastocarb
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
Carboplat
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Carbosin
Carbotec
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
|
DivK1c_000892
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
Nealorin
Neocarbo
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Ribocarbo
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
| 46 |
|
Topotecan |
Approved, Investigational |
Phase 2 |
|
119413-54-6, 123948-87-8 |
60700
|
|
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
123948-87-8
9 Dimethylaminomethyl 10 hydroxycamptothecin
9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin
9-Dimethylaminomethyl-10-hydroxycamptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
Hydrochloride, nogitecan
Hydrochloride, topotecan
LS-127395
MLS000759456
NCGC00178695-01
NChemBio.2007.10-comp24
|
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
Nogitecan hydrochloride
NSC609699
SK And F 104864 a
SK And F104864a
SK And F-104864-a
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SmithKline beecham brand OF topotecan hydrochloride
SMP2_000312
SMP2_000327
SMR000466344
TOPO
topotecan
Topotecan
Topotecan (BAN)
Topotecan [INN:BAN]
Topotecan Hcl
Topotecan hydrochloride
Topotecan Hydrochloride
Topotecan lactone
Topotecan Lactone
Topotecan monohydrochloride, (S)-isomer
Topotecan Monohydrochloride, (S)-Isomer
TOPOTECAN, HYCAMTIN
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
TPT
TTC
UNII-7M7YKX2N15
|
|
| 47 |
|
Tamoxifen |
Approved |
Phase 2 |
|
10540-29-1 |
2733526
|
|
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
10540-29-1
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-b-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-P-b-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-P-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
apo-Tamox
Apo-Tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Citrate, tamoxifen
cMAP_000044
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-tamoxifen
Gen-Tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
Lopac0_001203
LS-393
MLS001332535
MLS001332536
|
MolPort-003-850-384
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
NSC727681
Oncomox
Pms-Tamoxifen
PMS-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
Savient brand OF tamoxifen citrate
SMR000059172
Soltamox
Spectrum5_001417
Spectrum5_002043
ST50511785
T5648_SIGMA
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
tamoxifen
Tamoxifen
Tamoxifen (INN)
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifen citrate
Tamoxifen Citrate
Tamoxifene
Tamoxifène
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tocris-0999
Tomaxithen
TRANS FORM OF TAMOXIFEN
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
Zitazonium
|
|
| 48 |
|
Sargramostim |
Approved, Investigational |
Phase 2,Phase 1 |
|
123774-72-1, 83869-56-1 |
|
|
Synonyms:
123774-72-1
D05803
Leukine
Leukine (TN)
Recombinant human granulocyte-macrophage colony stimulating factor
rGM-CSF
|
rHu GM-CSF
Sargramostim
Sargramostim (genetical recombination)
Sargramostim (genetical recombination) (JAN)
Sargramostim (USAN/INN)
|
|
| 49 |
|
Aldesleukin |
Approved |
Phase 2 |
|
110942-02-4, 85898-30-2 |
|
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Aldesleukina
Interleukin-2 aldesleukin
|
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
|
|
| 50 |
|
Iodine |
Approved, Investigational |
Phase 1, Phase 2,Phase 2 |
|
7553-56-2 |
807
|
|
Synonyms:
diiodine
I2
Iode
Iodine-molecule
Iodio
iodo
|
Iodum
Jod
Jood
molecular iodine
Molecular iodine
Tincture iodine
|
|
Interventional clinical trials:
(show top 50)
(show all 82)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Radiation Therapy or Temozolomide in Treating Patients With Gliomas |
Completed |
NCT00182819
|
Phase 3 |
temozolomide |
| 2 |
Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma |
Completed |
NCT00003375
|
Phase 2, Phase 3 |
lomustine;procarbazine hydrochloride;vincristine sulfate |
| 3 |
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain |
Completed |
NCT00538850
|
Phase 3 |
Fentanyl sublingual spray;Placebo |
| 4 |
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors |
Completed |
NCT00369785
|
Phase 3 |
donepezil hydrochloride;Placebo |
| 5 |
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma |
Active, not recruiting |
NCT00978458
|
Phase 3 |
temozolomide |
| 6 |
Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas |
Unknown status |
NCT01024907
|
Phase 1, Phase 2 |
|
| 7 |
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme |
Unknown status |
NCT00892177
|
Phase 2 |
dasatinib |
| 8 |
Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors |
Completed |
NCT00003304
|
Phase 2 |
temozolomide |
| 9 |
Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma |
Completed |
NCT00003101
|
Phase 2 |
busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate |
| 10 |
Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors |
Completed |
NCT00003731
|
Phase 2 |
temozolomide |
| 11 |
Everolimus in Treating Patients With Recurrent Low-Grade Glioma |
Completed |
NCT00823459
|
Phase 2 |
Everolimus |
| 12 |
Temozolomide in Treating Patients With Low-Grade Glioma |
Completed |
NCT00313729
|
Phase 2 |
temozolomide |
| 13 |
Irinotecan in Treating Patients With Recurrent Glioma |
Completed |
NCT00003134
|
Phase 2 |
irinotecan hydrochloride |
| 14 |
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma |
Completed |
NCT00003616
|
Phase 1, Phase 2 |
irinotecan hydrochloride |
| 15 |
Sunitinib in Treating Patients With Recurrent Malignant Gliomas |
Completed |
NCT00499473
|
Phase 2 |
sunitinib malate |
| 16 |
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer |
Completed |
NCT00492089
|
Phase 2 |
bevacizumab;placebo |
| 17 |
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma |
Completed |
NCT00003467
|
Phase 2 |
carmustine;polifeprosan 20 with carmustine implant |
| 18 |
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer |
Completed |
NCT00007982
|
Phase 2 |
carmustine;cisplatin;cyclophosphamide;etoposide;thiotepa |
| 19 |
Bevacizumab in Recurrent Grade II and III Glioma |
Completed |
NCT01164189
|
Phase 2 |
Temozolomide |
| 20 |
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors |
Completed |
NCT01032200
|
Phase 2 |
Armodafinil |
| 21 |
Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors |
Completed |
NCT00629889
|
Phase 2 |
levetiracetam;pregabalin |
| 22 |
Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors |
Completed |
NCT00541138
|
Phase 2 |
carboplatin;tamoxifen citrate;topotecan hydrochloride |
| 23 |
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma |
Completed |
NCT00498927
|
Phase 2 |
temozolomide |
| 24 |
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas |
Completed |
NCT00274755
|
Phase 2 |
chemotherapy |
| 25 |
Carboplatin in Patients With Progressive Gliomas |
Completed |
NCT00002749
|
Phase 2 |
carboplatin |
| 26 |
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma |
Completed |
NCT00008008
|
Phase 2 |
cyclophosphamide;thiotepa |
| 27 |
Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma |
Completed |
NCT00005976
|
Phase 2 |
carboplatin;pyrazoloacridine |
| 28 |
Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma |
Completed |
NCT00004024
|
Phase 2 |
|
| 29 |
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor |
Completed |
NCT00070161
|
Phase 2 |
donepezil hydrochloride |
| 30 |
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers |
Completed |
NCT00002752
|
Phase 1, Phase 2 |
|
| 31 |
Temozolomide in Treating Patients With Progressive Low-Grade Glioma |
Completed |
NCT00003466
|
Phase 2 |
temozolomide |
| 32 |
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors |
Completed |
NCT00003461
|
Phase 1, Phase 2 |
|
| 33 |
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors |
Completed |
NCT00002608
|
Phase 2 |
cisplatin;doxorubicin hydrochloride;tamoxifen citrate |
| 34 |
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors |
Recruiting |
NCT00303849
|
Phase 1, Phase 2 |
Carboplatin;Etoposide Phosphate;Mannitol;Melphalan;Sodium Thiosulfate |
| 35 |
Temozolomide and Radiation Therapy in Treating Patients With Gliomas |
Active, not recruiting |
NCT00114140
|
Phase 2 |
Temozolomide |
| 36 |
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor |
Active, not recruiting |
NCT00049127
|
Phase 1, Phase 2 |
Imatinib Mesylate |
| 37 |
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma |
Active, not recruiting |
NCT01635283
|
Phase 2 |
|
| 38 |
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer |
Active, not recruiting |
NCT00445965
|
Phase 2 |
|
| 39 |
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma |
Terminated |
NCT00003472
|
Phase 2 |
Antineoplaston therapy (Atengenal + Astugenal) |
| 40 |
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma |
Terminated |
NCT01051557
|
Phase 1, Phase 2 |
Perifosine;Temsirolimus |
| 41 |
Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors |
Withdrawn |
NCT00005083
|
Phase 2 |
|
| 42 |
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas |
Unknown status |
NCT00083096
|
Phase 1 |
lonafarnib;temozolomide |
| 43 |
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors |
Unknown status |
NCT00002647
|
Phase 1 |
verteporfin |
| 44 |
Stereotactic Radiosurgery in Treating Patients With Brain Tumors |
Completed |
NCT00019578
|
Phase 1 |
|
| 45 |
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas |
Completed |
NCT02186509
|
Phase 1 |
Alisertib |
| 46 |
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma |
Completed |
NCT01119599
|
Phase 1 |
Gamma-Secretase Inhibitor RO4929097;Temozolomide |
| 47 |
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction |
Completed |
NCT00030498
|
Phase 1 |
erlotinib hydrochloride |
| 48 |
Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma |
Completed |
NCT00401024
|
Phase 1 |
imatinib mesylate |
| 49 |
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors |
Completed |
NCT00784914
|
Phase 1 |
temsirolimus |
| 50 |
Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma |
Completed |
NCT00730613
|
Phase 1 |
|
|
